The benefits of pemetrexed + carboplatin were maintained in elderly patients with advanced NSCLC. As seen in the Q-ITT population and the <70-year age group, elderly pemetrexed + carboplatin-treated patients experienced longer survival without toxicity than docetaxel + carboplatin-treated patients did. There were no statistically

significant between-treatment arm differences in OS, Peptide 17 ic50 PFS, or the response rate among elderly patients, among patients aged <70 years, and in the Q-ITT population; however, the response rate was numerically higher in pemetrexed + carboplatin-treated patients than in docetaxel + carboplatin-treated patients, and the between-arm response differences appeared greater in elderly patients than in the those aged <70 years and the Q-ITT population. This might be a reflection of greater variability due to the smaller number of patients in the ≥70-year age group. The retention of pemetrexed + carboplatin-related benefits in elderly patients is likely due to this regimen’s favorable AE profile. Elderly patients treated with pemetrexed + carboplatin experienced lower rates of most hematological AEs (i.e., neutropenia, leukopenia, lymphopenia, febrile neutropenia) XAV 939 than elderly patients treated with docetaxel + carboplatin. Moreover, there were reduced rates of alopecia and diarrhea among elderly patients treated with pemetrexed + carboplatin.

In both arms, the AE trends in the elderly mostly

Volasertib chemical structure mirrored those of the Q-ITT population and the <70-year age group. Importantly, there were no unexpected AEs in either treatment arm, nor were there on-study deaths among elderly patients. The between-arm toxicity profile difference was consistent across all age-group subsets. There was a slight Protein tyrosine phosphatase increase in selected toxicities (mucosal inflammation, diarrhea, neutropenia, and leukopenia) in the elderly age groups compared with the <70-year age-group subset, regardless of the treatment arm. This may have contributed to the improved survival without grade 4 toxicity and survival without grade 3 or 4 clinically important toxicity differences observed with respect to the magnitude of the HR in favor of pemetrexed + carboplatin. Subset analyses of pemetrexed registration trials showed that the benefit of pemetrexed is maintained in elderly advanced NSCLC patients without compromising tolerability [11, 12]. In elderly first-line NSCLC patients treated with pemetrexed + cisplatin, the rates of neutropenia, thrombocytopenia, and febrile neutropenia appeared to increase with age [11]. However, in all age groups, the <70-year age group, the ≥65-year age group, and ≥70-year age group in our trial, the rates of neutropenia (39.6, 38.2, 45.7, and 47.1 %, respectively), thrombocytopenia (14.2, 14.6, 14.3, and 11.